To, Date: January 16, 2026

The Listing Department

National Stock Exchange of India Limited

Exchange Plaza, Bandra Kurla Complex,

Bandra (East), Mumbai - 400051

Symbol: INFINIUM

Sub.: Press Release - Disclosure under Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015

Dear Madam/ Sir,

Pursuant to Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, please find enclosed herewith Press Release titled "**Infinium Pharmachem Ltd commissions Contrast Media Raw Materials Manufacturing Facility**".

The copy of the same is enclosed herewith for your records. The same will also be placed on the company's website.

Thanking You

Yours faithfully,

For Infinium Pharmachem Limited

Sanjaykumar Viththalbhai Patel

Digitally signed by Sanjaykumar Viththalbhai Patel
DN: c=IN, o=Personal, pseudonym=49963e9b58e64cda991e2d566c635f4b, 2.5.4.20=23c81667e595a2d0aec94e14ae7753db4bae2989b55956b1a1cb923a3411fcdb, postalCode=388325, st=Gujarat, cn=Sanjaykumar Viththalbhai Patel
Date: 2026.01.16 11:31:17 +05'30'

Sanjay Patel

Managing Director

DIN: 00370715

Infinium Pharmachem Ltd commissions Contrast Media Raw Materials Manufacturing Facility

Strengthening presence in high-margin, specialized iodine chemistry

Date: January 16, 2026

Infinium Pharmachem Ltd is pleased to announce the successful completion and commissioning of its new manufacturing facility for contrast media raw materials at **GIDC Sojitra, District Anand, Gujarat with effect from January 16, 2026**.

The commissioning represents an important step in the Company's forward integration strategy, enabling Infinium Pharmachem Ltd to enter the contrast media value chain. Leveraging its established expertise in iodine-based chemistry, the Company aims to address higher-value opportunities across a range of end-use applications.

The contrast media segment is expected to be a key growth driver. Over the next 3 years, the Company is targeting annual revenue of approximately ₹100 crore from this segment, with an anticipated EBITDA margin of around 30%. This will increase the blended EBITDA margin to around 20%.

This expansion marks a step-up into value-added contrast media–related offerings serving pharmaceutical, diagnostic imaging, and healthcare applications, aligned with the Company's long-term growth objectives.

About Infinium Pharmachem Limited

Infinium Pharmachem Limited (NSE- INFINIUM) is headquartered in Anand, Gujarat. The company is manufacturer of Iodine Derivative and Pharma Intermediates and Active Pharmaceutical Ingredients (APIs). The Company undertakes Contract Research and Manufacturing Services (CRAMS) to provide customized and fully confidential solutions to its clients.
